Last updated: February 13, 2026
What is NDC 55513-0002?
NDC 55513-0002 corresponds to Kuvan (sapropterin dihydrochloride), a medication indicated for phenylketonuria (PKU), a rare metabolic disorder. Approved by the FDA in 2007, Kuvan is a synthetic form of tetrahydrobiopterin (BH4), which acts as a co-factor in phenylalanine hydroxylase, enabling enzyme activity in PKU patients. It is marketed primarily by BioMarin Pharmaceutical Inc.
What is the current market size for Kuvan?
The PKU treatment market remains niche due to the rarity of the condition. The prevalence rate in the U.S. is approximately 1 in 10,000 to 15,000 live births, translating into around 20,000 identified patients, with estimated diagnosed patients around 10,000 to 15,000.
Current market specifics:
| Item |
Details |
| US Patient Population (estimated) |
10,000 – 15,000 |
| Annual prescription volume |
~2,000 – 3,000 (varies based on adherence and access) |
| Average dosing per patient |
10 g/month (typical), varies with age and weight |
| Estimated annual market value per patient |
$56,000 (based on current pricing) |
| Total U.S. market size |
Approximately $560 million to $840 million annually |
What are the current pricing trends?
The wholesale acquisition cost (WAC) is approximately $28,000 per month per patient in the U.S., equating to roughly $336,000 annually per patient (per data from IQVIA and drug pricing references). Patient access programs can reduce out-of-pocket costs, but the list price remains high due to small patient populations and complex manufacturing.
Pricing points:
| Pricing Factor |
Details |
| WAC per month |
~$28,000 |
| WAC per year |
~$336,000 |
| Cost per gram (typical dose) |
~$2,800 |
| Market-driven variations |
Discounts for Medicaid, commercial insurance, and patient assistance |
What are the key market drivers?
- Regulatory approvals in non-U.S. markets: Kuvan has approvals in Europe, Japan, and other regions, expanding potential revenue streams.
- New formulations and indications: Ongoing research for combination therapies or expanded age ranges could extend the patent life or market appeal.
- Competitive landscape: Limited competition due to the rare disease status, but emerging biotech startups and gene therapy approaches are potential future threats.
What are the potential threats and competition?
- Biosimilars and generics: No biosimilars currently exist for Kuvan, protecting near-term market share.
- Gene therapy developments: Research in gene editing (e.g., CRISPR) for PKU could disrupt treatment paradigms.
- Pricing pressures: Payers could negotiate for lower prices or impose stricter reimbursement criteria, influencing revenue.
What are the key patent considerations?
- Kuvan's primary patent protecting its formulation and delivery methods is expected to expire around 2025–2027.
- Patent extensions or new formulations could prolong exclusivity; biosimilar development could erode pricing power beyond 2027.
- BioMarin's pipeline and licensing strategies influence future market composition.
What are the price projection trends?
Given current high prices, projections hinge on:
| Scenario |
Assumptions |
Price Outlook |
| Base case |
No new competitors; patent protections maintained until 2027 |
Stable pricing at current levels (~$28,000/month) |
| Optimistic |
Patent extension or new formulations; increased demand |
Slight price increases (~5-10% annually) |
| Pessimistic |
Entry of biosimilars or generics; reimbursement pressure increases |
Price declines 20-30% post-biosimilar approval |
Summary of projections (next 5 years)
| Year |
Estimated Price per Patient/month |
Market Size (patients) |
Revenue Estimates |
| 2023 |
$28,000 |
2,500 |
~$840 million |
| 2024 |
$28,000 |
2,700 |
~$907 million |
| 2025 |
$28,000 |
3,000 |
~$1.00 billion |
| 2026 |
Slight decline if biosimilars emerge |
3,000 |
Potential decline to ~$700–800 million if biosimilar entry occurs |
| 2027 |
Price stabilization or decline with biosimilars |
3,000 |
Downward pressure expected, ~20-30% reduction in price |
Key Takeaways
- Kuvan remains a high-cost, niche pharmaceutical with a stable but limited patient market.
- Pricing is linked to rare disease status, with current list prices around $28,000/month.
- Market growth depends primarily on geographic expansion and new formulations.
- Patent expirations around 2025–2027 pose future threat; biosimilar entry could compress prices.
- Gene therapies are emerging as potential disruptors over the next decade, possibly replacing current treatment schemas.
FAQs
Q1: How sustainable are Kuvan’s current prices?
Current pricing is sustained by the rarity of PKU and patent protections, but upcoming patent expiries and biosimilar developments threaten price stability.
Q2: What is the estimated global market for Kuvan?
Including Europe and Japan, the global market could reach approximately 1.5 times the US market, around $1.2–$1.6 billion annually, depending on regional approvals and access.
Q3: Are there cheaper alternatives for PKU treatment?
Diet management remains primary, but drug alternatives are limited. Some patients use sapropterin as adjunct therapy, and experimental gene therapies aim to provide a more permanent solution.
Q4: How do biosimilars affect the market?
Biosimilars could enter post-patent expiration, potentially reducing prices by 20–30% or more, depending on market uptake and regulatory approval.
Q5: What future innovations could influence Kuvan’s market?
Gene editing approaches (like CRISPR) have the potential to cure PKU, which would drastically alter the market landscape.
References:
[1] IQVIA Data, 2023.
[2] FDA Approval Documents for Kuvan, 2007.
[3] BioMarin Annual Reports, 2022.
[4] European Medicines Agency, 2022.
[5] Market Research Report: Rare Disease Drugs, 2023.
